XLOHIGH SIGNALFINANCIAL10-K

XLO executed a 1-for-14 reverse stock split in March 2026 while dramatically improving its financial position with revenue surging 590% and cash more than doubling to $137.5M.

The reverse stock split signals previous distress and potential Nasdaq delisting concerns, but the company appears to have successfully raised substantial capital and significantly improved operations. The shift from going concern warnings to capital needs language, combined with dramatically improved cash flow and revenue growth, suggests XLO may have secured a major partnership or financing that has stabilized the business.

Comparing 2026-03-23 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

XLO's financial transformation is remarkable, with revenue exploding from $6.3M to $43.8M (+590%) and cash position more than doubling to $137.5M, while operating cash flow losses improved dramatically from -$18.4M to -$5.0M. Total assets and liabilities both roughly doubled, suggesting significant business expansion or a major transaction, while net losses decreased substantially from -$58.2M to -$35.0M. The overall picture indicates a company that has likely secured major funding or partnerships, transitioning from financial distress to a much stronger capital position with rapidly growing revenue.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+1338.9%
$36K→$518K

Capital expenditure jumped 1338.9% — major investment cycle underway; assess returns on deployment.

Revenue
P&L
+589.9%
$6.3M→$43.8M

Strong top-line growth of 589.9% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+148.7%
$55.3M→$137.5M

Cash position surged 148.7% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+140.8%
$60.2M→$145.0M

Current assets grew 140.8% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
+123.3%
$53.5M→$119.4M

Liabilities grew 123.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+117.6%
$71.1M→$154.7M

Asset base grew 117.6% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+106.4%
$27.3M→$56.3M

Current liabilities surged 106.4% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
+100.4%
$17.6M→$35.3M

Equity base grew 100.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
+72.8%
-$18.4M→-$5.0M

Operating cash flow surged 72.8% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+39.8%
-$58.2M→-$35.0M

Net income grew 39.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-11
ADDED
Reverse Stock Split Unless otherwise indicated, all share amounts and per share amounts have been adjusted retroactively in this Annual Report on Form 10-K to give effect to the 1-for-14 reverse stock split of our common stock effected on March 13, 2026.
These risks include, but are not limited to, the following: We will need to obtain substantial additional capital in the future to finance our operations and complete the development of any current or future product candidates.
If we fail to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
The recently implemented reverse stock split of our common stock may not achieve the intended benefits and could have a materially adverse effect on the market price of our common stock.
We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
+7 more — sign up free →
REMOVED
Hoffmann-La Roche Ltd; our expectations regarding milestones, option-related fees and other contingent payments under our collaboration agreement with AbbVie and our license agreement with Gilead; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and the impact of general economic conditions, including inflation.
These risks include, but are not limited to, the following: Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
If we are unable to raise sufficient additional capital in the near term, we will need to implement additional cost reduction strategies, which could include delaying, limiting, reducing or eliminating both internal and external costs related to our operations and research and development programs.
We face risk related to our reliance on our current and any future third-party contract development and manufacturing organizations, or CDMOs.
For example, the CDMO on which we rely may not continue to meet regulatory requirements, may have limited capacity and may experience interruptions in supply, any of which could adversely affect our development and commercialization plans for our product candidates.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →